Pulmobreathe is a combined drug used for inflammatory diseases of the respiratory tract. The activity of the drug is determined by two active substances - acetylcysteine and ambroxol.
Acetylcysteine is a mucolytic, expectorant and antioxidant agent. The uniqueness of the molecule lies in the direct effect on the structure of sputum. Acetylcysteine reduces viscosity, improves excretion and increases the amount of sputum of any kind - mucous, purulent, mucopurulent. By suppressing the formation of free radicals, a weak anti-inflammatory effect is realized. The composition of Pulmobreathe contains 200 mg of acetylcysteine.
Ambroxol is the most prescribed mucolytic agent, both monotherapy and as part of a combination treatment or drug. The substance has a pronounced expectorant effect, which is provided due to the normalization of sputum components. Ambroxol stimulates the synthesis and production of lung surfactant, which is necessary for the protection and assimilation of oxygen. It is also worth noting the anti-inflammatory, local immunomodulatory, bronchodilatory effects. Ambroxol accelerates the penetration of antibiotics into the lung tissue. As a component of the drug, Pulmobreathe ambroxol is contained in a dose of 30 mg.
The combination of active ingredients in Pulmobreathe is reasonable and effective. Acetylcysteine and ambroxol potentiate the therapeutic effect of each other, therefore, the speed of recovery increases and the risk of developing complications of the disease decreases.
The dose of active substances of the drug is intended for adults and children over 12 years of age. Provided that it is taken three times, a daily dose of ambroxol and acetylcysteine, which are part of Pulmobreathe, is provided.
When applying, it is necessary to pay attention to the manifestation of adverse reactions and report them to the attending physician. Usually, the drug is well tolerated when the recommended dosages are observed.
Pulmobreathe significantly facilitates the course of the disease, accelerates the restoration of bronchopulmonary functions, has a high safety profile and good tolerance.
Active ingredients:
Excipients: lactose, monohydrate; povidone (K-30); anhydrous colloidal silicon dioxide; crospovidone; sodium lauryl sulfate; hydrogenated vegetable oil;
Shell composition: Opadry® 200 Orange (polyvinyl alcohol; talc; sunset yellow dye FCF (E 110); titanium dioxide (E 171); glycerol monostearate; polyvinyl acetate phthalate; sodium lauryl sulfate; sodium bicarbonate); Opaglos® 2 (sodium carboxymethyl cellulose; maltodextrin; glucose, monohydrate; lecithin; vanillin).
Treatment of acute and chronic diseases of the respiratory tract, accompanied by impaired bronchial secretion and evacuation of secretions: including in acute and chronic bronchitis, chronic obstructive pulmonary diseases, pneumonia, bronchiectasis, bronchial asthma, cystic fibrosis, laryngitis, tracheitis.
Hypersensitivity to ambroxol, acetylcysteine or other components of the drug.
Peptic ulcer and duodenal ulcer in the acute stage.
Hemoptysis, pulmonary hemorrhage, severe exacerbation of bronchial asthma.
Method of administration and dosage
Doses for adults and children over 12 years old: 1 tablet 3 times a day.
Do not exceed the recommended dose.
The duration of treatment should not exceed 5-7 days without consulting a doctor.
There are no data on cases of overdose of oral dosage forms of acetylcysteine and ambroxol.
Ambroxol was well tolerated after oral administration up to 25 mg / kg / day. In case of an overdose with ambroxol or acetylcysteine, no severe signs of intoxication were observed.
Symptoms known from rare overdose reports and cases of misuse are consistent with known adverse reactions.
Symptoms: nausea, vomiting, short-term anxiety, diarrhea, hypersalivation, decreased blood pressure. There is a risk of hypersecretion in children.
Treatment: symptomatic treatment is recommended.
Keep out of the reach of children in the original packaging at a temperature not exceeding 25 ° C.
Shelf life is 4 years.
There are no reviews for this product.